ArticleJournal of periodontology2026
Immunological and periodontal benefits of prebiotic polydextrose in rats with induced periodontitis.
Article in Journal of periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrebiotic therapy is a promising approach for managing periodontitis due to its potential benefits in modulating the microbiome and the immune response. This study aimed to evaluate the effects of the prebiotic (PREB) polydextrose (PDX) on the development of experimental periodontitis (EP) in rats.
methodsA total of 44 male adult rats (Rattus norvegicus, albinus, Wistar) were randomly allocated into groups (n = 11) C (control), PREB, EP, and EP/PREB. The PREB and EP/PREB groups received 2 g of PDX/day in the drinking water for 44 days. The EP and EP/PREB groups received cotton ligatures around mandibular first molars (M1) for 14 days. Microtomographic, histopathological, and immunohistochemical analyses of periodontal and intestinal tissues were performed. Data were analyzed statistically (p < 0.05).
resultsThe EP/PREB group showed less alveolar bone destruction than the EP group. The EP/PREB group exhibited higher expressions of IL-10 and a lower number of TRAP (tartrate-resistant acid phosphatase)-positive cells than the EP group in periodontal tissues. The EP/PREB group had increased villus heights in the duodenum and ileum, increased crypt depths in the duodenum, and higher expressions of occludin in all intestinal portions, claudin-1 in the jejunum, IL-10 in the duodenum, and lower expressions of IL-1β in the jejunum compared with the EP group.
conclusionPolydextrose exerted a protective effect against alveolar bone resorption and favorably modulated both local and systemic immune-inflammatory response in rats with experimental periodontitis. PLAIN LANGUAGE SUMMARY: Prebiotic therapy has emerged as a promising approach for treating periodontitis, an immunoinflammatory disease associated with a dysbiotic biofilm that leads to the loss of the supporting structures of the teeth. This is because prebiotics can positively influence the balance of bacteria in the body and the immune system's response. However, current understanding of its potential effects and mechanisms of action remains limited in periodontal therapy. The effects of the prebiotic polydextrose (PDX) on periodontal tissues remain unknown. The results of the present study show that the prebiotic PDX can minimize alveolar bone loss and improve bone microarchitecture through modulation of the immune-inflammatory response in both intestinal and periodontal tissues of rats with experimental periodontitis. Our findings suggest that the prebiotic PDX may represent a beneficial adjunctive strategy for managing periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.